PI3 Kinase p110 Alpha Polyklonaler Antikörper
PI3 Kinase p110 Alpha Polyklonal Antikörper für WB, ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human, Maus, Ratte
Anwendung
WB, CoIP, ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 27921-1-AP
Synonyme
Geprüfte Anwendungen
| Erfolgreiche Detektion in WB | Jurkat-Zellen, Maushirngewebe, NIH/3T3-Zellen, Rattenhirngewebe |
Empfohlene Verdünnung
| Anwendung | Verdünnung |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Veröffentlichte Anwendungen
| WB | See 19 publications below |
| CoIP | See 1 publications below |
Produktinformation
27921-1-AP bindet in WB, CoIP, ELISA PI3 Kinase p110 Alpha und zeigt Reaktivität mit human, Maus, Ratten
| Getestete Reaktivität | human, Maus, Ratte |
| In Publikationen genannte Reaktivität | human, Maus, Ratte |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Polyklonal |
| Typ | Antikörper |
| Immunogen | PI3 Kinase p110 Alpha fusion protein Ag27539 |
| Vollständiger Name | phosphoinositide-3-kinase, catalytic, alpha polypeptide |
| Berechnetes Molekulargewicht | 1068 aa, 124 kDa |
| Beobachtetes Molekulargewicht | 110 kDa |
| GenBank-Zugangsnummer | BC113601 |
| Gene symbol | PIK3CA |
| Gene ID (NCBI) | 5290 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Antigen-Affinitätsreinigung |
| Lagerungspuffer | PBS with 0.02% sodium azide and 50% glycerol |
| Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
PIK3CA belongs to the PI3/PI4-kinase family. It phosphorylates PtdIns, PtdIns4P and PtdIns(4,5)P2 with a preference for PtdIns(4,5)P2. Defects in PIK3CA are associated with colorectal cancer (CRC). Defects in PIK3CA are associated with breast cancer. Defects in PIK3CA are associated with ovarian cancer. Defects in PIK3CA may underlie hepatocellular carcinoma (HCC). Defects in PIK3CA are a cause of keratosis seborrheic (KERSEB).
Protokolle
| PRODUKTSPEZIFISCHE PROTOKOLLE | |
|---|---|
| WB protocol for PI3 Kinase p110 Alpha antibody 27921-1-AP | Protokoll herunterladen |
| STANDARD-PROTOKOLLE | |
|---|---|
| Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
| Species | Application | Title |
|---|---|---|
J Ethnopharmacol Xiao-Luo-Wan treats propylthiouracil-induced goiter with hypothyroidism in rats through the PI3K-AKT/RAS pathways based on UPLC/MS and network pharmacology. | ||
Heliyon Anticancer potential of grifolin in lung cancer treatment through PI3K/AKT pathway inhibition | ||
JCI Insight Regulatory T-cell and neutrophil extracellular traps interaction contributes to the development of immunosuppression in sepsis | ||
Anticancer Drugs STK214947, a novel indole alkaloids, inhibits HeLa and SK-HEP-1 cells survival and EMT process by blocking the Notch3 and Akt signals | ||
J Immunother Vitexin Inhibits TNBC Progression and Metastasis by Modulating Macrophage Polarization Through EGFR Signaling | ||
Eur J Pharmacol Novel Applications of Metformin in the Treatment of Septic Myocardial Injury Based on Metabolomics and Network Pharmacology |

